PharmaShots | Incisive News in 3 Shots

Subscribe Now

refractory

$Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021$

Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

June 3, 2021

$Janssen's Teclistamab Receives the US FDA's Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma$

Janssen's Teclistamab Receives the US FDA's Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

June 2, 2021

$BMS' Abecma (idecabtagene vicleucel) Receives the Health Canada's Approval as the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma$

BMS' Abecma (idecabtagene vicleucel) Receives the Health Canada's Approval as the First Anti-BCMA CAR T Cell Therapy for Relapsed...

June 1, 2021

$Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma$

Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma

May 20, 2021

$Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma$

Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma

April 19, 2021

$Oncopeptides' Pepaxto (melphalan flufenamide) Receives the US FDA's Approval for Triple Class Refractory Multiple Myeloma$

Oncopeptides' Pepaxto (melphalan flufenamide) Receives the US FDA's Approval for Triple Class Refractory Multiple Myeloma

March 1, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us